BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 20378854)

  • 1. Short communication: the cardiac myosin binding protein C Arg502Trp mutation: a common cause of hypertrophic cardiomyopathy.
    Saltzman AJ; Mancini-DiNardo D; Li C; Chung WK; Ho CY; Hurst S; Wynn J; Care M; Hamilton RM; Seidman GW; Gorham J; McDonough B; Sparks E; Seidman JG; Seidman CE; Rehm HL
    Circ Res; 2010 May; 106(9):1549-52. PubMed ID: 20378854
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Founder mutation in myosin-binding protein C with an early onset and a high penetrance in males.
    Méndez I; Fernández AI; Espinosa MÁ; Cuenca S; Lorca R; Rodríguez JF; Tamargo M; García-Montero M; Gómez C; Vilches S; Vázquez N; Álvarez R; Medrano C; Yotti R; Fernández-Avilés F; Bermejo J
    Open Heart; 2021 Sep; 8(2):. PubMed ID: 34588271
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nationwide study on hypertrophic cardiomyopathy in Iceland: evidence of a MYBPC3 founder mutation.
    Adalsteinsdottir B; Teekakirikul P; Maron BJ; Burke MA; Gudbjartsson DF; Holm H; Stefansson K; DePalma SR; Mazaika E; McDonough B; Danielsen R; Seidman JG; Seidman CE; Gunnarsson GT
    Circulation; 2014 Sep; 130(14):1158-67. PubMed ID: 25078086
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A founder MYBPC3 mutation results in HCM with a high risk of sudden death after the fourth decade of life.
    Calore C; De Bortoli M; Romualdi C; Lorenzon A; Angelini A; Basso C; Thiene G; Iliceto S; Rampazzo A; Melacini P
    J Med Genet; 2015 May; 52(5):338-47. PubMed ID: 25740977
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gender- and age-related differences in distinct phenotypes of hypertrophic cardiomyopathy-associated mutation MYBPC3-E334K.
    Yang QL; Zuo L; Ma ZL; Lei CH; Zhu XL; Wang XY; Wang B; Zhao XL; Zhang J; Wang Y; Zhang YM; Liu LW
    Heart Vessels; 2021 Oct; 36(10):1525-1535. PubMed ID: 33830315
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel phenotype-genotype correlations of hypertrophic cardiomyopathy caused by mutation in α-actin and myosin-binding protein genes in three unrelated Chinese families.
    Yang QL; Bian YY; Wang B; Zuo L; Zhou MY; Shao H; Zhang YM; Liu LW
    J Cardiol; 2019 May; 73(5):438-444. PubMed ID: 30600190
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Myosin binding protein C mutations and compound heterozygosity in hypertrophic cardiomyopathy.
    Van Driest SL; Vasile VC; Ommen SR; Will ML; Tajik AJ; Gersh BJ; Ackerman MJ
    J Am Coll Cardiol; 2004 Nov; 44(9):1903-10. PubMed ID: 15519027
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Spectrum of clinical phenotypes and gene variants in cardiac myosin-binding protein C mutation carriers with hypertrophic cardiomyopathy.
    Erdmann J; Raible J; Maki-Abadi J; Hummel M; Hammann J; Wollnik B; Frantz E; Fleck E; Hetzer R; Regitz-Zagrosek V
    J Am Coll Cardiol; 2001 Aug; 38(2):322-30. PubMed ID: 11499719
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Compound heterozygosity deteriorates phenotypes of hypertrophic cardiomyopathy with founder MYBPC3 mutation: evidence from patients and zebrafish models.
    Hodatsu A; Konno T; Hayashi K; Funada A; Fujita T; Nagata Y; Fujino N; Kawashiri MA; Yamagishi M
    Am J Physiol Heart Circ Physiol; 2014 Dec; 307(11):H1594-604. PubMed ID: 25281569
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypertrophic cardiomyopathy clinical phenotype is independent of gene mutation and mutation dosage.
    Viswanathan SK; Sanders HK; McNamara JW; Jagadeesan A; Jahangir A; Tajik AJ; Sadayappan S
    PLoS One; 2017; 12(11):e0187948. PubMed ID: 29121657
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reevaluation of the South Asian
    Harper AR; Bowman M; Hayesmoore JBG; Sage H; Salatino S; Blair E; Campbell C; Currie B; Goel A; McGuire K; Ormondroyd E; Sergeant K; Waring A; Woodley J; Kramer CM; Neubauer S; Farrall M; Watkins H; Thomson KL;
    Circ Genom Precis Med; 2020 Jun; 13(3):e002783. PubMed ID: 32163302
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel deletions in MYH7 and MYBPC3 identified in Indian families with familial hypertrophic cardiomyopathy.
    Waldmüller S; Sakthivel S; Saadi AV; Selignow C; Rakesh PG; Golubenko M; Joseph PK; Padmakumar R; Richard P; Schwartz K; Tharakan JM; Rajamanickam C; Vosberg HP
    J Mol Cell Cardiol; 2003 Jun; 35(6):623-36. PubMed ID: 12788380
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Characteristics and Long-Term Outcome of Hypertrophic Cardiomyopathy in Individuals With a MYBPC3 (Myosin-Binding Protein C) Founder Mutation.
    van Velzen HG; Schinkel AFL; Oldenburg RA; van Slegtenhorst MA; Frohn-Mulder IME; van der Velden J; Michels M
    Circ Cardiovasc Genet; 2017 Aug; 10(4):. PubMed ID: 28794111
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Meta-Analysis of Penetrance and Systematic Review on Transition to Disease in Genetic Hypertrophic Cardiomyopathy.
    Topriceanu CC; Pereira AC; Moon JC; Captur G; Ho CY
    Circulation; 2024 Jan; 149(2):107-123. PubMed ID: 37929589
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of systolic dysfunction in genotyped hypertrophic cardiomyopathy.
    Fujino N; Konno T; Hayashi K; Hodatsu A; Fujita T; Tsuda T; Nagata Y; Kawashiri MA; Ino H; Yamagishi M
    Clin Cardiol; 2013 Mar; 36(3):160-5. PubMed ID: 23197398
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypertrophic cardiomyopathy in a Portuguese population: mutations in the myosin-binding protein C gene.
    Cardim N; Perrot A; Santos S; Morgado P; Pádua M; Ferreira S; Reis RP; Monteiro C; Ferreira T; Correia JM; Osterziel KJ
    Rev Port Cardiol; 2005 Dec; 24(12):1463-76. PubMed ID: 16566405
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Comparative study of gene mutation between Chinese patients with familial and sporadic hypertrophic cardiomyopathy].
    Pan GZ; Liu WL; Hu DY; Xie WL; Zhu TG; Li L; Li CL; Bian H
    Zhonghua Yi Xue Za Zhi; 2006 Nov; 86(42):2998-3001. PubMed ID: 17288815
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiac myosin binding protein-C variants in paediatric-onset hypertrophic cardiomyopathy: natural history and clinical outcomes.
    Field E; Norrish G; Acquaah V; Dady K; Cicerchia MN; Ochoa JP; Syrris P; McLeod K; McGowan R; Fell H; Lopes LR; Cervi E; Kaski JPP
    J Med Genet; 2022 Aug; 59(8):768-775. PubMed ID: 34400558
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypertrophic cardiomyopathy in myosin-binding protein C (
    Adalsteinsdottir B; Burke M; Maron BJ; Danielsen R; Lopez B; Diez J; Jarolim P; Seidman J; Seidman CE; Ho CY; Gunnarsson GT
    Open Heart; 2020; 7(1):e001220. PubMed ID: 32341788
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Whole MYBPC3 NGS sequencing as a molecular strategy to improve the efficiency of molecular diagnosis of patients with hypertrophic cardiomyopathy.
    Janin A; Chanavat V; Rollat-Farnier PA; Bardel C; Nguyen K; Chevalier P; Eicher JC; Faivre L; Piard J; Albert E; Nony S; Millat G
    Hum Mutat; 2020 Feb; 41(2):465-475. PubMed ID: 31730716
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.